These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 33795712)

  • 1. Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells.
    Abedin MR; Powers K; Aiardo R; Barua D; Barua S
    Sci Rep; 2021 Apr; 11(1):7347. PubMed ID: 33795712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-conjugated pH-sensitive liposomes for HER-2 positive breast cancer: development, characterization,
    Raikwar S; Yadav V; Jain S; Jain SK
    J Liposome Res; 2024 Jun; 34(2):239-263. PubMed ID: 37594466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles.
    Barua S; Mitragotri S
    ACS Nano; 2013 Nov; 7(11):9558-70. PubMed ID: 24053162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies.
    Koopaei MN; Dinarvand R; Amini M; Rabbani H; Emami S; Ostad SN; Atyabi F
    Int J Nanomedicine; 2011; 6():1903-12. PubMed ID: 21931485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell lines.
    Gabrielson M; Tina E
    Oncol Rep; 2013 Apr; 29(4):1268-74. PubMed ID: 23354756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thermo- and pH-responsive targeted lipid-coated mesoporous nano silica platform for dual delivery of paclitaxel and gemcitabine to overcome HER2-positive breast cancer.
    Nasri N; Saharkhiz S; Dini G; Yousefnia S
    Int J Pharm; 2023 Dec; 648():123606. PubMed ID: 37972671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological effects of site specific conjugated anti-human epidermal growth factor receptor 2-antibody drug conjugate using unnatural amino acid technology].
    Liang XJ; Gong LY; Zhou F; Zhou DM; Zhu JJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):797-804. PubMed ID: 31624380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by
    Sharma R; Kameswaran M; Pandey U; Dash A
    J Cancer Res Ther; 2020; 16(6):1426-1434. PubMed ID: 33342808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
    Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
    Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells.
    Noh JK; Naeem M; Cao J; Lee EH; Kim MS; Jung Y; Yoo JW
    Int J Pharm; 2016 Nov; 513(1-2):543-553. PubMed ID: 27686050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
    Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
    J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab-mediated selective delivery for platinum drug to HER2-positive breast cancer cells.
    Huang R; Sun Y; Gao Q; Wang Q; Sun B
    Anticancer Drugs; 2015 Oct; 26(9):957-63. PubMed ID: 26186063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
    Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
    Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
    Costantini DL; Villani DF; Vallis KA; Reilly RM
    J Nucl Med; 2010 Mar; 51(3):477-83. PubMed ID: 20150272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells.
    Yu K; Zhao J; Zhang Z; Gao Y; Zhou Y; Teng L; Li Y
    Int J Pharm; 2016 Jan; 497(1-2):78-87. PubMed ID: 26617314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.
    Xiong J; Han S; Ding S; He J; Zhang H
    Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
    Marcinkowska M; Stanczyk M; Janaszewska A; Sobierajska E; Chworos A; Klajnert-Maculewicz B
    Pharm Res; 2019 Sep; 36(11):154. PubMed ID: 31482205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
    Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
    Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
    Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
    Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.